Osteocalcin
Evidence: B/C — Meaningful Human EvidenceEndocrine / Calcium-Bone Axis Signaling
Evidence Snapshot
What this grade covers
B applies to osteocalcin's foundational biosynthesis/assay-mechanism science (native, form-general). C applies to any claim from the undercarboxylated-osteocalcin/insulin-secretion association (Funakoshi 2020), which is specific to one Japanese diabetic cohort and must not be generalized to other proteoforms, insulin sensitivity, other populations, or any treatment outcome. No dedicated bone-turnover-marker professional-society guideline is present in the current source base; routine clinical-use claims should remain general pending that source.
Regulatory Context
Native osteocalcin is an endogenous osteoblast-secreted protein with no approved therapeutic product. It is used clinically as a bone-formation biomarker.
Research Takeaway
Osteocalcin (bone Gla protein, BGLAP gene product) is synthesized by osteoblasts.
See all 4 evidence claims →Quick Summary
Osteocalcin is a protein made by bone-building cells, used as a marker of bone turnover and, more speculatively, studied for a possible metabolic role. It remains a single scientific subject; carboxylated and undercarboxylated osteocalcin are modification states of the same molecule, not separate identities.
Mechanism & Research Overview
Osteocalcin is a protein made by bone-building cells, used as a marker of bone turnover and, more speculatively, studied for a possible metabolic role. It remains a single scientific subject; carboxylated and undercarboxylated osteocalcin are modification states of the same molecule, not separate identities.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Osteocalcin (bone Gla protein, BGLAP gene product) is synthesized by osteoblasts.
Sources: Cell-free translation of the vitamin K-dependent bone protein osteocalcin
Supported
Circulating osteocalcin can be measured by immunoassays with differing specificity for carboxylated (Gla-containing) versus total or undercarboxylated osteocalcin; assay validation work has addressed measurement of the carboxylated form specifically, a documented source of cross-study variability.
Sources: Validation of the bone Gla protein (osteocalcin) assay
Supported
In a cross-sectional Japanese cohort study (N=75), undercarboxylated osteocalcin correlated positively with insulin secretion, independent of BMI, among participants with diabetes mellitus.
Supported
The Funakoshi et al. 2020 finding is specific to undercarboxylated osteocalcin, insulin secretion (not sensitivity), and a Japanese cohort with diabetes mellitus; it does not by itself establish effects for carboxylated or total osteocalcin, for insulin sensitivity, for non-diabetic or non-Japanese populations, or for any treatment outcome.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Many older/lower-quality osteocalcin studies do not specify carboxylation state or assay; such findings cannot be safely attributed to a specific proteoform in future claims.Safety Consideration
Any future claim about osteocalcin's proposed metabolic/endocrine signaling role beyond insulin secretion in the one specific studied cohort should not be asserted without independent, human-specific primary support.
Research Areas Being Studied
Research areas discussed on this page reflect the Endocrine / Calcium-Bone Axis Signaling category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Undercarboxylated osteocalcin correlates with insulin secretion in Japanese individuals with diabetes (2020):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Undercarboxylated osteocalcin correlates with insulin secretion in Japanese individuals with diabetes | 2020 | 75 Japanese adults (mean age 65±11y, BMI 24.9±3.8), 3 groups of 25 by 75g-OGTT: normal glucose tolerance, impaired glucose metabolism, diabetes mellitus | Undercarboxylated osteocalcin (ucOC) correlated positively with insulin secretion, independent of BMI, specifically among participants with diabetes mellitus. Narrow, form-specific finding: specific to undercarboxylated osteocalcin, insulin secretion (not sensitivity), and this Japanese diabetic cohort — does not establish effects for carboxylated/total osteocalcin, insulin sensitivity, other populations, or any treatment outcome. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
No Regulatory Documents & Official Trial Registries Listed Yet
This section will be updated as sources are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published research about Osteocalcin and does not provide medical advice, an individualized treatment recommendation, or dosing instructions.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for Osteocalcin
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.